Physician profile
Cara Robb
NPI 1912423989
$5,965.14
in general payments reported to CMS, 2019-2025
35 companies · $22.24 in 2025
The $22.24 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,062 · 2022: $1,399 · 2023: $448 · 2024: $34.16 · 2025: $22.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,190.47 | 2021 | |
| Sk Life Science, INC. | $621.41 | 2021-2023 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $556.03 | 2021-2022 | |
| Si-Bone, INC. | $545.17 | 2022 | |
| Abbvie INC. | $423.61 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $335.68 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $243.84 | 2021-2024 | |
| Genzyme Corporation | $177.79 | 2021 | |
| Alexion Pharmaceuticals, INC. | $166.43 | 2021-2022 | |
| Amgen INC. | $154.87 | 2021 | |
| Lundbeck LLC | $138.28 | 2021 | |
| Allergan, INC. | $136.38 | 2021 | |
| Ucb, INC. | $131.22 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $123.73 | 2023 | Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $106.40 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $91.95 | 2023 | Valtoco |
| Biohaven Pharmaceutical Holding Company Ltd. | $91.58 | 2022 | |
| Acorda Therapeutics, INC | $89.90 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $88.30 | 2021 | |
| Kyowa Kirin, INC. | $87.07 | 2021 | |
| Csl Behring | $80.00 | 2022 | |
| Biogen, INC. | $77.23 | 2021 | |
| Lilly USA, LLC | $41.96 | 2021 | |
| Emd Serono, INC. | $35.65 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $33.66 | 2022 | |
| Sunovion Pharmaceuticals INC. | $33.43 | 2021 | |
| Upsher-Smith Laboratories LLC | $28.50 | 2021 | |
| Mallinckrodt Hospital Products INC. | $26.08 | 2023 | Acthar |
| Janssen Pharmaceuticals, INC | $20.71 | 2022 | |
| Genentech USA, INC. | $17.06 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $16.78 | 2022 | |
| Horizon Therapeutics Plc | $16.05 | 2021 | |
| Abbott Laboratories | $14.90 | 2021 | |
| Celgene Corporation | $11.67 | 2021 | |
| Neurocrine Biosciences, INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Robb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.